Advertisement
Advertisement
Trending on CancerNetwork
1
141 DESTINY-Breast06 Post Hoc Analysis by Physician’s Choice of Chemotherapy: Efficacy and Safety of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in Hormone Receptor–Positive, HER2-Low or -Ultralow Metastatic Breast Cancer
2
142 Exploratory Biomarker Analysis of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in HER2-Low/Ultralow, Hormone Receptor–Positive Metastatic Breast Cancer in DESTINY-Breast06
3
Leveraging the CD44-SPP1 Axis in Muscle-Invasive Bladder Cancer
4
Managing Bispecific Logistics: Remote Monitoring and CRS Mitigation Strategies
5